Flamel Technologies S.A. (NASDAQ:AVDL) - Research analysts at SunTrust Banks dropped their Q2 2017 earnings per share estimates for shares of Flamel Technologies in a research note issued on Wednesday. SunTrust Banks analyst J. Boris now forecasts that the company will post earnings of $0.04 per share for the quarter, down from their previous estimate of $0.07. SunTrust Banks also issued estimates for Flamel Technologies’ Q3 2017 earnings at ($0.02) EPS, Q4 2017 earnings at $0.01 EPS and FY2017 earnings at $0.30 EPS.
Flamel Technologies (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.16. The business had revenue of $46.30 million during the quarter, compared to analysts’ expectations of $45.17 million. Flamel Technologies had a positive return on equity of 14.49% and a negative net margin of 7.28%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis.
ILLEGAL ACTIVITY NOTICE: “Analysts Set Expectations for Flamel Technologies S.A.’s Q2 2017 Earnings (NASDAQ:AVDL)” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/19/analysts-set-expectations-for-flamel-technologies-s-a-s-q2-2017-earnings-nasdaqavdl-updated.html.
Separately, Zacks Investment Research lowered shares of Flamel Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 12th.
Shares of Flamel Technologies (NASDAQ:AVDL) opened at 8.81 on Monday. The company’s market capitalization is $364.52 million. Flamel Technologies has a 52 week low of $8.75 and a 52 week high of $15.45. The company has a 50 day moving average price of $10.38 and a 200 day moving average price of $10.02.
A number of hedge funds have recently bought and sold shares of the company. US Bancorp DE acquired a new stake in Flamel Technologies during the first quarter valued at $121,000. Sei Investments Co. increased its stake in Flamel Technologies by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after buying an additional 2,900 shares in the last quarter. Trexquant Investment LP increased its stake in Flamel Technologies by 30.7% in the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock valued at $336,000 after buying an additional 7,169 shares in the last quarter. Alps Advisors Inc. acquired a new stake in Flamel Technologies during the second quarter valued at $411,000. Finally, State of New Jersey Common Pension Fund D increased its stake in Flamel Technologies by 27.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock valued at $464,000 after buying an additional 9,175 shares in the last quarter. 71.03% of the stock is owned by institutional investors and hedge funds.
In other Flamel Technologies news, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $10.68, for a total value of $2,787,480.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Guillaume Cerutti sold 26,560 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $10.46, for a total transaction of $277,817.60. Following the completion of the sale, the director now directly owns 23,440 shares of the company’s stock, valued at $245,182.40. The disclosure for this sale can be found here. Insiders own 5.07% of the company’s stock.
About Flamel Technologies
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.
